Cell type-selective carriers for targeted pharmacological inhibition of Rho-/actin-dependent leukocyte recruitment into the alveolar space after blunt chest trauma (A04)

(用于靶向药物抑制钝性胸部创伤后依赖于Rho/肌动蛋白的白细胞重新聚集到肺泡腔的细胞类型选择性载体)侧重于选择性地调节巨噬细胞和中性粒细胞在肺泡腔的招募和功能的策略。该项目建立在发现单核/巨噬细胞选择性载体(C3botE174Q)的基础上，将Rho-、肌动蛋白-和CXCR2-抑制剂转移到细胞中。将开发具有类似治疗选择的中性粒细胞选择性转运体，并在小鼠胸部创伤模型中确定其对炎症反应的影响。此外，对比剂的靶向输送将使MRI能够监测细胞迁移的寿命。

(Cell type-selective carriers for targeted pharmacological inhibition of Rho-/actin-dependent leukocyte recruitment into the alveolar space after blunt chest trauma) focuses on strategies to selectively modulate recruitment and function of both macrophages and neutrophils in the alveolar space. The project builds on the discovery of monocyte/macrophage-selective carriers (C3botE174Q) to transfer Rho-, actin-, and CXCR2-inhibitors into the cells. Neutrophil-selective transporters with similar therapeutic options will be developed and their effects on the inflammatory response determined in a murine thorax trauma model. Furthermore, targeted delivery of contrast agents will enable lifetime monitoring of cell migration by MRI.